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Abstract
Advanced glycation end products (AGEs) have been implicated in diverse pathological settings of many diabetic
complications, and the possible mechanisms have been widely reported. However, the relationship between AGEs and
pancreatic b-cell dysfunction is still poorly understood. Recent studies have shown that AGEs can impair b-cell function by
inducing apoptosis or decreasing insulin secretion. Our previous research revealed that AGEs could significantly down-
regulate insulin transcription and reduce b-cell glucose-stimulated insulin secretion (GSIS). Here, we investigated the
possible mechanisms underlying AGE-related suppression of insulin synthesis. In the rat pancreatic b-cell line INS-1, we
found that AGEs induced dephosphorylation of Foxo1 and increased its accumulation in the nucleus. The translocation of
Foxo1 subsequently inhibited pancreatic-duodenal homeobox factor-1 (Pdx-1) levels in both nuclear and cytoplasmic
compartments. We observed that with AGEs treatment, Pdx-1 protein levels decreased after 4 h, but there was no change in
the Pdx-1 mRNA level or promoter activity at the same time point; this demonstrated that the decrease in Pdx-1 expression
was not regulated at the transcriptional level. In our study, the decrease in Pdx-1 protein level was related to its reduced
stability, overexpression of DN-Foxo1 could partially reverse the inhibition of Pdx-1 expression. Pretreatment with AGEs
receptor (RAGE) antibody also prevented the AGE-induced diminution of Pdx-1 protein and insulin mRNA expression. In
summary, AGEs induced nuclear accumulation of Foxo1; this in turn reduced Pdx-1 expression by decreasing its protein
stability, ultimately affecting insulin synthesis.
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Introduction
Type 2 diabetes arises when the endocrine pancreas fail to
secrete sufficient insulin to cope with metabolic demands, due to
acquired b-cell secretory dysfunction and insulin synthesis
suppression [1]. Glucotoxicity, lipotoxicity, and glucolipotoxicity
are secondary phenomena that are proposed to play important
roles in all forms of type 2 diabetes [2]. Advanced glycation end
products (AGEs) in islets are an important mechanism for
glucotoxicity [3]. A large body of evidence suggests that people
with diabetes have higher levels of AGEs than nondiabetic subjects
because of hyperglycemia [4,5,6]. Clinical investigations have
indicated that AGEs are independently correlated with the
proinsulin-to-insulin ratio (P/I ratio), which is a strong predictor
of b-cell dysfunction [3]. In animal models, several diabetic
complications, including diabetes-associated nephropathy [7],
retinopathy [8], neuropathy [9], and atherosclerosis [10], have
been linked to AGEs. Moreover, concrete mechanisms that link
AGEs with these complications have been defined. However, little
research has focused on the cytotoxic effects of AGEs on b-cell.
Only a few studies have demonstrated that AGEs can impair b-cell
secretory functions [11], lower insulin content [12], or induce
apoptosis in INS-1 cells and primary islets [8,13,14]. A possible
explanation for these observations is that AGEs might induce the
expression of inducible nitric oxide synthase (iNOS), leading to
inhibition of cytochrome c oxidase and ATP synthesis. Another
possibility is the generation of reactive oxygen species (ROS)
induced by AGEs. Currently, the relationship between AGEs and
b-cell is still poorly defined; therefore, clearly establishing the role
of AGEs in b-cell damage and further revealing the possible
mechanisms responsible for this damage is very necessary.
Pdx-1 plays a significant role in both pancreatic development
and maintenance of b-cell function [15]. Targeted disruption of
this transcription factor in b-cell leads to diabetes, whereas
reducing its expression affects insulin expression and secretion
[16,17]. Numerous studies have focused on Pdx-1, which is
considered to be a principal insulin regulator, and the regulation
mode between Pdx-1 and insulin has been clearly demonstrated.
In Pdx-1 allele-inactivated (Pdx-1
+/-) mice, b-cell develops
hyperplasia but fails to increase insulin content [18]. Adenoviral
expression of Pdx-1 in liver cells induced endogenous insulin
expression, which had been confirmed to be biologically active
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18782[19]. In the INS-1 cell line and pancreatic islets, delivery of a small
interfering RNA specific for Pdx-1 decreased insulin mRNA levels
to approximately 40% of normal levels [20]. Current research
suggests that a decrease in the expression of Pdx-1 will inevitably
lead to a deficiency in insulin transcription, since the binding of
Pdx-1 on the gene promoter of insulin will decline [21,22].
Foxo1 is a transcription factor of the forkhead family that
plays a critical role in cellular differentiation, proliferation,
apoptosis, and stress resistance [23]. Foxo1 controls two
important processes in the pathogenesis of type 2 diabetes:
hepatic glucose production and b-cell compensation of insulin
resistance [24]. Recent studies have revealed that Foxo1
negatively regulated Pdx-1 by modulating Pdx-1 subcellular
localization or suppressing Pdx-1 gene transcription [25]. The
two transcription factors exhibit mutually exclusive patterns of
nuclear localization in b-cell; constitutive nuclear expression of a
mutant Foxo1 is associated with the lack of Pdx-1 expression
[26,27]. However, the type of molecular events that occur
between Foxo1 and Pdx-1 remains unclear. Here, we propose
that Foxo1 may contribute to the decrease in Pdx-1 stability
under AGEs stimulation; this may provide a new regulation
model for the interaction between these factors.
In this study, we utilize the insulin-secreting b-cell line INS-1 to
test the hypothesis that AGEs may down-regulate Pdx-1 protein
stability; this in turn leads to a reduction in Pdx-1 protein levels,
ultimately contributing to a deficiency in insulin synthesis.
Results
The effects of GS on insulin promoter activity,
transcription, and content
The transcription level and content of insulin are important
indices used to evaluate the function of pancreatic b-cell.
Inhibition of insulin transcription leads to a deficiency in its
synthesis, and thus, the glucose metabolic balance cannot be
maintained. In the present study, when we treated the INS-1 cells
with GS for 24 h, Insulin1 and Insulin2 transcription was greatly
repressed. As shown by the real-time PCR results, Insulin1 and 2
mRNA expression sharply decreased to 32% and 38%,
respectively (Fig. 1A). In addition, we examined the effects of
GS on insulin promoter activity by using the luciferase reporter
gene assay. Compared to the NG-treated cells, the GS-treated
cells showed an approximately 35% decrease in normalized
insulin promoter luciferase activity (Fig. 1B). The total cellular
insulin content was also significantly decreased in the GS group
(Fig. 1C).
GS inhibited Pdx-1 protein expression
Although many transcription factors have been implicated in
the regulation of insulin transcription, three b-cell-specific
transcription regulators, namely, Pdx-1, neurogenic differentia-
tion 1 (NeuroD1), and V-maf musculoaponeurotic fibrosarcoma
oncogene homologue A (MafA), have been demonstrated to play
a crucial role in insulin transcription regulation and pancreatic b-
cell function. We determined the effects of GS on all of these
transcription factors and found that Pdx-1 expression was most
inhibited. As shown in (Fig. 2A), Pdx-1 protein levels decreased in
a dose-dependent manner. The levels of Pdx-1 protein in INS-1
cells treated with GS also appeared to decrease in a time-
dependent manner (Fig. 2B). Since Pdx-1, as a transcription
factor, can shuttle between the nucleus and cytoplasm and its
activity is directly related to its level in the nucleus, we next
examined the intracellular localization of Pdx-1 after GS
stimulation. Consistent with our finding of a reduction in total
Pdx-1 protein expression, Pdx-1 protein levels decreased both in
nuclear and cytoplasmic extracts at 4 h, and persisted to 12 h
(Fig. 2C).
GS down-regulated Pdx-1 at the post-translational level
To further explore the mechanism of GS-induced reduction of
Pdx-1 expression, we determined the effects of GS on Pdx-1
mRNA expression and promoter activity. With GS treatment for
4 h, Pdx-1 mRNA levels showed no difference compared with
NG group (Fig. 3A), but Pdx-1 protein levels were reduced at this
time point (Fig. 2B). We transfected INS-1 cells with the pGL3-
Pdx-1 luciferase reporter construct, then treated them with NG or
GS and found that GS had no influence on Pdx-1 promoter
activity either (Fig. 3B). On the basis of these results, we suspected
that GS would negatively affect Pdx-1 protein stability. To
confirm this possibility, we evaluated Pdx-1 protein expression
stability in cells treated with NG or GS for 0, 4, 8, and 12 h;
protein synthesis was inhibited by using cycloheximide. After de
novo protein synthesis was blocked, Pdx-1 protein levels
Figure 1. Glycated serum (GS) inhibited insulin synthesis. (A)
Real-time PCR analysis was performed to measure Insulin1 and Insulin2
mRNA 24 h after treatment with 10% GS. Relative quantification was
used to calculate the change in insulin mRNA, which was depicted as
the fold change. (B) INS-1 cells transfected with pGL3-insulin constructs
for 24 h, followed by treatment with nonglycated (NG) or 10% GS for a
further 24 h. Lysates were harvested for the luciferase assay. (C) INS-1
cells cultured with NG or 10% GS for 24 h. Insulin content was
measured after acidified ethanol extraction. Data are represented of
three separate experiments. **p,0.01 vs. NG.
doi:10.1371/journal.pone.0018782.g001
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suggested that GS regulated Pdx-1 expression at the post-
translational level by increasing its degradation.
GS treatment resulted in Foxo1 nuclear accumulation
contributing to a decrease in Pdx-1 stability
Pdx-1 is potentially modified by several post-translational
mechanisms such as phosphorylation, glycosylation, and sumoy-
lation. However, the exact underlying mechanism remains largely
unknown. Considering direct regulation and excluding co-
localization between Foxo1 and Pdx-1, there is a high likelihood
that AGEs decrease Pdx-1 protein stability via Foxo1. First, we
aimed to confirm that Foxo1 was indeed activated by GS in INS-
1 cells. We treated INS-1 cells with NG and GS for 4, 8, and 12
h. The cells were then collected for protein extraction and
western blot analyses. The phosphorylation levels of Foxo1
reduced in a time-dependent manner, whereas the nuclear
accumulation of Foxo1 increased (Fig. 4A). To ensure the
involvement of Foxo1 in the process of GS-induced decline in
Pdx-1 expression, we overexpressed DN-Foxo1, which could
compete with endogenous Foxo1. After a 24 h transfection, the
transfected cells were treated with NG or GS for a further 24 h.
In this case, the reduction in Pdx-1 protein expression was greatly
reversed (Fig. 4B). These data suggested that the decrease in Pdx-
1 protein stability caused by GS exposure was due to the nuclear
accumulation of Foxo1.
Inhibition of RAGE blocked the effects of GS on Pdx-1
expression and insulin transcription
RAGE can mediate AGEs signaling in many cell types;
however, its role in pancreatic b-cell, particularly in insulin
synthesis deficiency caused by GS stimulation in INS-1 cells, is
not clear. We therefore pretreated cells with RAGE antibody for
1 h to block RAGE activity, and then treated the cells with NG
or GS for a further 24 h. As shown by the results of real-time
PCR (Fig. 5A), RAGE antibody partially reversed the decrease in
insulin mRNA levels under GS treatment; however, the antibody
had no effect on the expression of insulin. Furthermore, in the
presence of RAGE antibody, the decrease in Pdx-1 protein was
almost completely reversed. No protective effect on Pdx-1
expression was observed when cells were co-incubated with IgG
(Fig. 5B).
Discussion
In the present study, we demonstrated that GS treatment could
cause a sharp decrease in Pdx-1 protein levels. Since there was no
change in Pdx-1 mRNA and promoter activity, but there was an
increase in the protein degradation rate. Therefore, we suggested
that GS down-regulated Pdx-1 protein expression at a post-
translational level. The decrease in Pdx-1 stability was related to
the accumulation of Foxo1 in the nucleus and could be reversed by
overexpression of DN-Foxo1. Ultimately, Pdx-1 expression
deficiency would lead to a decrease in insulin mRNA, promoter
activity and content.
We and other researchers have previously shown that AGEs
can damage pancreatic b-cell function by decreasing cell
viability, thereby reducing insulin secretion and content. Zhao
et al. have reported that AGEs inhibited cytochrome c oxidase
and ATP production; this could be a possible explanation for
the defect in insulin secretion. Minsu et al. have attributed this
loss of b-cell function to an increased production of ROS.
However, little is known about the connection between AGEs
and the obstacle to insulin synthesis. Here, we showed that GS
can significantly down-regulated Pdx-1 protein levels, which in
turn led to the inhibition of its role in promoting insulin
transcription.
Eukaryotic cell protein synthesis is under complex regulation.
Gene transcription constitutes only a part of the regulatory
mechanism. Therefore, other control mechanisms, in particular
post-translational modification of proteins, may be particularly
Figure 2. Glycated serum (GS) inhibited Pdx-1 protein expression. (A) INS-1 cells were treated with nonglycated (NG; control) serum or with
varying concentrations of GS for 24 h and then harvested for western blot analysis. (B) INS-1 cells were treated with NG or 10% GS and harvested at
the indicated time point for western blot analysis. (C) INS-1 cells were treated with NG or 10% GS for 4, 8, or 12 h. Cytoplasmic and nuclear protein
was extracted, and then Pdx-1 determination was conducted.
doi:10.1371/journal.pone.0018782.g002
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number of studies have indicated that it could be regulated at the
transcriptional, post-transcriptional, and post-translational level.
Robertson et al. have shown that the post-transcriptional loss of
Pdx-1 mRNA is the primary mechanism for the loss of Pdx-1
protein induced by oxidative stress in HIT-T15 cells [28]. Two
serine residues (Ser
61 and Ser
66) are located in the transactivation
domain of Pdx-1 and are conserved among different species [17].
We observed that there was no decrease in Pdx-1 mRNA level and
promoter activity compared with NG group, but at the same time,
Pdx-1 protein expression was strongly repressed. Furthermore, as
de novo protein synthesis was inhibited by cyclocheximide, GS
could induce more rapid degradation of Pdx-1; this suggested that
GS clearly down-regulated Pdx-1 expression at the post-transla-
tional level. However, the exact post-translational modification
involved in, the conditions when this occurs, the underlying
mechanism, and the effect on Pdx-1 function remain largely
unresolved. Previous studies have shown that phosphorylation of
Ser
61 and Ser
66 could increase the rate of Pdx-1 degradation and
decrease the half-life of Pdx-1 protein. In our investigation, the
question of whether the reduced stability of Pdx-1 is related to an
increased phosphorylation of these two sites needs to be further
explored.
We revealed that the diminished level of Pdx-1 was associated
with Foxo1 nuclear accumulation. With GS treatment, Foxo1
dephosphorylation increased, and it was shuttled to the nucleus.
The mechanism of GS-induced Foxo1 nuclear accumulation is
completely unknown. Kawamori et al. have reported that under
oxidative stress conditions, activation of the c-Jun N-terminal
kinase (JNK) pathway induced the nuclear and cytoplasmic
transposition of Pdx-1. Foxo1 played a role as a mediator between
the JNK pathway and Pdx-1. However, GS could not activate the
JNK pathway in our experiment. Only a minor increase in ROS
was observed, and this suggested that the decreased expression of
Pdx-1 was probably not related to oxidative stress. Indeed,
oxidative stress is thought to be the main causal factor in the
pathogenesis of diabetic complications related to AGEs. The
possible reason for such weak oxidative stress in our study could be
the preparation of GS. Compared with glucose, ribose is probably
a much stronger oxidant and can cause oxidative stress in the islets
very quickly, whereas many months of culture may be required to
induce oxidative stress with high glucose [3].
RAGE antibody partially reversed the defective of Pdx-1
expression and insulin biosynthesis. According to this partially
protective effects, it is important to understand the relationship
between AGEs and their receptors. AGE-R1 is largely responsible
for the clearing of AGEs. The role of AGE-R2, R3, and the
scavenger receptors (SR-B CD36) are less well defined [4,29].
RAGE and other receptors appear to mediate cell signaling and
activate a stress response leading to cellular dysfunction [30].
RAGE, as a member of the immunoglobulin superfamily, is
expressed in a few cell types only. We have confirmed that the
RAGE gene is present in rat pancreatic b-cell (INS-1 cells) and its
expression increased with GS stimulation. Pretreatment of cells
with RAGE antibody for 1 h partially prevented the decrease in
insulin mRNA and Pdx-1 protein expression. The reason why
RAGE antibody does not fully block Pdx-1 and insulin decrease is
probably due to the complexity of the AGE receptor system. Many
receptors involve in and these receptors occupy both positive and
negative roles in actions of AGEs. Therefore, it is difficult to
determine which receptors participate in the process of AGE-
related deterioration of insulin synthesis. Although RAGE plays a
prominent role in this pathway, it is not the only receptor that is
involved. The cytosolic domain of RAGE is critical for RAGE-
dependent signal transduction; however, only Dia-1 and ERK
have been confirmed to interact with RAGE [31,32]. In our study,
the gap between RAGE and Foxo1 still needs to be further
researched.
Figure 3. Glycated serum (GS) down-regulated Pdx-1 at the
post-translational level. (A) Real-time PCR analysis was performed to
measure Pdx-1 mRNA 4 h after treatment with nonglycated (NG) or
10% GS. (B) INS-1 cells were transiently transfected with the pGL3-Pdx-1
construct for 24 h. Luciferase activity was assayed after a 24 h
incubation with NG or 10% GS. (C) INS-1 cells were treated with NG
or 10% GS together with cyclocheximide (50 mg/mL) for the indicated
periods of time. All the treated cells were then harvested and lysed for
western blot analyses. Representative immunoblots and a graph
showing protein levels of Pdx-1 relative to a-tubulin are presented.
*p,0.05 vs. NG; **p,0.01 vs. NG.
doi:10.1371/journal.pone.0018782.g003
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diabetic complications, AGEs can directly impair pancreatic b-cell
function by inhibiting insulin synthesis. We attribute these effects
to a reduction in the expression of the key insulin transcription
factor Pdx-1. Pdx-1 protein expression deficiency is not due to the
inhibition of its transcription, but due to the decrease in its protein
stability. Thus, the present study uncovers a new mechanism that
might contribute to the AGE-induced inhibition of insulin
synthesis.
Materials and Methods
AGE-fetal bovine serum preparation
Glycated serum (GS) was prepared as described previously [30].
Fetal bovine serum (FBS; Hyclone, Logan, UT) was incubated
under sterile conditions with D-glucose (90 g/L) at 37uC for 3
weeks. Unincorporated sugars were then removed by dialysis
against phosphate-buffered saline (PBS). Control nonglycated
serum (NG) was incubated under the same conditions but without
Figure 4. Glycated serum (GS) promoted Foxo1 nuclear accumulation to reduce Pdx-1 stability. (A) INS-1 cells were treated with
nonglycated (NG) or 10% GS for the indicated periods of time. All the cells were collected for total protein and nuclear protein extraction. Western
blot assay was used to detect the phosphorylated-Foxo1, total Foxo1, and nuclear Foxo1. (B) INS-1 cells overexpressing DN-Foxo1 construct were
cultured for 24 h and then treated with nonglycated (NG) or 10% glycated serum (GS) for another 24 h. Pdx-1 protein level was determined by
western blot assay. Representative immunoblots and a graph showing the protein levels of Pdx-1 relative to a-tubulin are presented. Data are
represented of three separate experiments. **p,0.01 vs. GS, vector-transfected group.
doi:10.1371/journal.pone.0018782.g004
Figure 5. RAGE antibody reversed glycated serum (GS)-induced impairment of Pdx-1 protein expression and insulin mRNA
expression. (A) INS-1 cells were pretreated with RAGE antibody for 1 h and then treated with nonglycated (NG) or 10% GS for a further 24 h. Insulin
mRNA was measured by real-time PCR assay. (B) With the same treatment, Pdx-1 protein level was determined by western blot assay. Representative
immunoblots and a graph showing the protein levels of Pdx-1 relative to b-actin are presented. Data are represented of three separate experiments.
*p,0.05 vs. the GS IgG Insulin1 group; #p,0.05 vs. the GS IgG Insulin2 group; *p,0.05 vs. the GS IgG group.
doi:10.1371/journal.pone.0018782.g005
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vitro study revealed that the reagents contained less than 0.2 ng/
mL of endotoxin.
Cell culture
INS-1 cells, a rat insulinoma cell line [14,33], were cultured in
RPMI-1640 medium (Invitrogen, Grand Island, NY) with
11.1 mM D-glucose supplemented with 10% FBS, 100 U/mL
penicillin, 100 mg/mL streptomycin, 10 mM HEPES, 2 mM L-
glutamine, 1 mM sodium pyruvate, and 50 mM b-mercaptoeth-
anol (Sigma-Aldrich, St. Louis, MO). All cell culturing was
performed in a Thermo tissue-culture incubator that provided an
environment of 95% O2/5% CO2 gas. Before addition of GS, the
cells were gently washed in PBS. NG or GS was added to the
appropriate experiments. Cells were incubated for an additional
indicated time.
Real-time RT-PCR
INS-1 cells were cultured and treated as described above. Total
RNA was extracted using Trizol reagent (Invitrogen). First-strand
cDNA synthesis was performed using 1 mg of total RNA and an
avian myeloblastosis virus reverse transcription system. The
primers were designed using the software Primer Express (Applied
Biosystems, Foster City, CA). Real-time quantitative PCR was
performed using the SYBR Green PCR Master Mix and ABI
Prism 7000 Sequence Detection System (Applied Biosystems). All
data was analyzed using the expression of b-actin as a reference.
Plasmid construction
The pGL3-insulin, pGL3-Pdx-1, and DN-Foxo1 plasmids
described in this study were available in our laboratory. The two
luciferase reporter constructs contain -2000 bp of insulin promoter
or homology region 2 (PH2) domain of the Pdx-1 promoter [34].
The DN-Foxo1 construct lacks a transactivation domain;
therefore, although it cannot activate its target, it can bind its
target gene [25].
Western blot analysis
INS-1 cells were cultured and treated as described above, then
lysed with ice-cold lysis buffer containing the following reagents:
50 mM Tris-HCl (pH 7.4), 1% NP-40, 150 mM NaCl, 1 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, and complete
proteinase inhibitor (one tablet per 10 mL; Roche Molecular
Biochemicals). After protein content determination, western
blotting was performed as described previously [35]. Individual
immunoblots were probed with antibodies to mouse anti-RAGE
monoclonal antibody (Santa Cruz Biotechnology) diluted to 1:800,
rabbit anti-Pdx-1 (Upstate) monoclonal antibody diluted to
1:4000, rabbit anti-phosphorylation-Foxo1 (Cell Signalling) mono-
clonal antibody diluted to 1:800, or rabbit anti-Foxo1 (Santa Cruz
Biotechnology) monoclonal antibody diluted to 1:1000. Target
protein levels were quantified relative to the levels of the control
protein, mouse anti-b-actin (Sigma-Aldrich, St. Louis, MO)
monoclonal antibody diluted to 1:5000, mouse anti-a-tubulin
(Sigma-Aldrich) monoclonal antibody diluted to 1:5000, and goat
anti-lamin B (Santa Cruz Biotechnology) monoclonal antibody
diluted to 1:800.
Insulin content
INS-1 cells were seeded in 24-well plates. After 24 h, cells were
washed twice with PBS (pH 7.4) at 0uC and extracted with acid/
ethanol (0.15 M HCl in 75% ethanol in H2O) for 16 h at 0uC.
Supernatants were collected and stored at 280uC until insulin
determination was carried out by ELISA. The results were
normalized to the total protein concentration.
Statistical analysis
Comparisons were performed using Student’s t-test between
pairs of groups, or ANOVA for multiple group comparison.
Results are presented as means 6 SEM. A p value of less than 0.05
was considered to be statistically significant.
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